ASCO GU 2022 - Results from #80

Viewing 81-100 of 316 articles

ASCO GU 2022: Management of Rare Variants in Genitourinary Cancers: Systemic Therapy for Rare Variants of Urothelial Cancer

ASCO GU 2022: Impact of Provider Education on Prostate Cancer Genetic Counseling Referrals

ASCO GU 2022: A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2022: Characteristics of Prostate Cancer Survivors Exposed to ADT and Enrolled in a Fall Prevention Exercise Trial: Comparison of Men With Confirmed Fall History to Men With Fall Risk Factors

ASCO GU 2022: DS-7300 (B7-H3 DXd-ADC) in Patients With Metastatic Castration-Resistant Prostate Cancer: A Subgroup Analysis of a Phase 1/2 Multicenter Study

ASCO GU 2022: Factors Associated With Gene Mutation Testing in United States Veterans With Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2022: Local Therapies for Variant Histology in Bladder Cancer

ASCO GU 2022: Discussion on the ARASENS and PRESIDE Trials

ASCO GU 2022: A Quantitative Synthesis of Disparities in the Inclusion of Racial/Ethnic Minorities and Older Adults in Prostate Cancer Clinical Trials Over the Last Three Decades

ASCO GU 2022: Tailoring 4Kscore Thresholds to Multiparametric MRI Results

ASCO GU 2022: Financial Toxicity and Its Effect on Screening for Prostate and Colon Cancer

ASCO GU 2022: Endocrine Tumors of the Genitourinary Tract

ASCO GU 2022: Homing in on Tumor Antigens With Antibody-Drug Conjugates in Advanced Urothelial Cancer: Basic Principles

ASCO GU 2022: A Phase 3, Randomized, Open-Label, Multicenter, Global Study of the Efficacy and Safety of Durvalumab + Tremelimumab + Enfortumab Vedotin or Durvalumab + EV for Neoadjuvant Treatment in Cisplatin-Ineligible MIBC (VOLGA)

ASCO GU 2022: Adjuvant Infigratinib As Targeted Therapy for Patients With Muscle-Invasive Urothelial Carcinoma Harboring Susceptible FGFR3 Genetic Alterations: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial (PROOF 302)

ASCO GU 2022: PIVOT IO 009: A Phase 3, Randomized Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin Versus NIVO Alone Versus Standard of Care in Patients With MIBC Who Are Cisplatin-Ineligible

ASCO GU 2022: SunRISe-1: Phase 2b Study of TAR-200 Plus Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Nonmuscle-Invasive Bladder Cancer Unresponsive to BCG Who Are Ineligible for or Decline Radical Cystectomy

ASCO GU 2022: TROPiCS-04: Study of Sacituzumab Govitecan in Patients With Locally Advanced Unresectable or Metastatic Urothelial Cancer That Has Progressed After Prior Platinum and Checkpoint Inhibitor Therapy

ASCO GU 2022: Study EV-302: A Two-Arm, Open-Label, Randomized Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Previously Untreated Advanced Urothelial Carcinoma

ASCO GU 2022: Systemic Therapy for the Management of Rare Prostate Cancer Variants

1
2
3
4
5
6
7
8
9
10